![\"Three](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/10\/24_07_05-three-people-standing-on-boxes-in-a-desert-looking-through-telescopes-_mf-dload-gettyimages.jpeg\"\/)
<\/p>\n
Image source: Getty Images.<\/p>\n
1. Kenvue is a boring consumer-staples business<\/p>\n
Kenvue was created when it was spun off from “Dividend King”<\/a> Johnson & Johnson. (A Dividend King is a company that has raised its dividend annually for 50-plus consecutive years.) That left J&J operating a drug and medical-device company and Kenvue operating J&J’s over-the-counter business.<\/p>\n Kenvue is a consumer-staples company, with iconic brands like Band-Aid, Johnson’s Shampoo, Aveeno, and Tylenol. However, right now, that last brand has gotten a lot of negative attention after it was singled out by members of the Trump administration as presenting a potential health issue for the baby if taken during pregnancy.<\/p>\n Today’s Change<\/p>\n (-0.60%) $-0.09<\/p>\n Current Price<\/p>\n $15.00<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $29B<\/p>\n Day’s Range<\/p>\n $14.98 – $15.33<\/p>\n 52wk Range<\/p>\n $14.05 – $25.17<\/p>\n Volume<\/p>\n 20M<\/p>\n Avg Vol<\/p>\n 29M<\/p>\n Gross Margin<\/p>\n 58.12%<\/p>\n Dividend Yield<\/p>\n 0.05%<\/p>\n That attention has resulted in Kenvue’s stock price plunging. The stock price drop pushed the dividend yield<\/a> up to 5.5%.<\/p>\n It is still a young business, for sure, but Kenvue has a strong stable of brands and products to which customers are loyal. This isn’t a fly-by-night company, and the negativity probably represents an emotional pendulum swing that’s gone too far. It’s true that the business hasn’t been performing particularly well in 2025 and recently lowered its full-year guidance, but even good brands go through weak periods.<\/p>\n It seems highly likely that this consumer-staples company will muddle through this period in one piece while continuing to reward investors for sticking around. That, by the way, is exactly what former parent J&J has provided for decades. A $1,000 investment will get you around 66 shares of Kenvue stock.<\/p>\n 2. Medtronic is closing in on a big dividend achievement<\/p>\n Johnson & Johnson is a Dividend King because it has increased its dividend for over five decades. Medtronic’s streak is at 48 years, so it’s just two years shy of that incredible achievement. The company isn’t planning to fall short, noting that it specifically stated that a planned business spinoff<\/a> of its diabetes division won’t lead to a change in its dividend policy.<\/p>\n The spinoff, however, is part of an important business overhaul. Medtronic, which makes medical devices<\/a>, has been working through a period of slow growth. Now it has new products coming out and is looking to focus on only its most profitable businesses.<\/p>\n Diabetes doesn’t have the same margins as the rest of the company, and the spinoff is expected to be instantly accretive to earnings. This spinoff and other changes being made should position the company for stronger growth in the years ahead.<\/p>\n Today’s Change<\/p>\n (-0.48%) $-0.45<\/p>\n Current Price<\/p>\n $93.76<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $120B<\/p>\n Day’s Range<\/p>\n $93.29 – $94.95<\/p>\n 52wk Range<\/p>\n $79.29 – $99.37<\/p>\n Volume<\/p>\n 148K<\/p>\n Avg Vol<\/p>\n 7M<\/p>\n Gross Margin<\/p>\n 59.81%<\/p>\n Dividend Yield<\/p>\n 0.03%<\/p>\n That said, Wall Street is taking a show-me attitude. Medtronic’s yield is a historically elevated 3% or so. If you like fairly boring dividend stocks, $1,000 will net you around 10 shares of Medtronic while the company works to get back into investors’ good graces.<\/p>\n 3. Pfizer is a high-risk\/high-reward dividend stock<\/p>\n Pfizer has the highest yield here at nearly 7%. However, the dividend-payout ratio<\/a> is hovering worryingly close to 100%.<\/p>\n The pharmaceutical giant has cut its dividend before, specifically following the large acquisition of Wyeth. Given that it’s again working on a big acquisition of Metsera, there’s a risk that the dividend gets a haircut.<\/p>\n Today’s Change<\/p>\n (0.36%) $0.09<\/p>\n Current Price<\/p>\n $24.76<\/p>\n Key Data Points<\/p>\n Market Cap<\/p>\n $141B<\/p>\n Day’s Range<\/p>\n $24.68 – $24.83<\/p>\n 52wk Range<\/p>\n $20.91 – $29.17<\/p>\n Volume<\/p>\n 27M<\/p>\n Avg Vol<\/p>\n 49M<\/p>\n Gross Margin<\/p>\n 67.34%<\/p>\n Dividend Yield<\/p>\n 0.07%<\/p>\n When you add upcoming patent expirations to the list of issues, you can see why investors are worried. But Pfizer is one of the largest and most resilient drug companies<\/a> on the planet, and what’s happening to the business right now isn’t unusual for a drug company.<\/p>\n If you shift your view and look at it as a turnaround stock, it could be worth buying. The high yield, in this case, is simply a sign that the stock is deeply unloved today. But even if there’s a dividend cut, a dividend is likely to continue being paid. If history is any guide, the dividend will start to grow again after a reset.<\/p>\n<\/p>\n
<\/p>\n
<\/p>\n